Voyager Names Steven Hyman To Board
This article was originally published in Scrip
Voyager Therapeutics, Inc., a gene therapy company focusing on the CNS, has appointed Steven Hyman to its board of directors. With over 20 years of scientific leadership experience, Hyman has been president of the Society for Neuroscience and since 2012; he has been director of the Stanley Centre for Psychiatric Research at the Broad Institute of Harvard and MIT. Previously Hyman was the director of the US National Institute of Mental Health and was also the founding president of the International Neuroethics Society.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.